Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
AstraZeneca
McKinsey
Dow

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Eluxadoline - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for eluxadoline and what is the scope of patent protection?

Eluxadoline is the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eluxadoline has one hundred and thirty-eight patent family members in thirty-eight countries.

There are two drug master file entries for eluxadoline. One supplier is listed for this compound.

Recent Clinical Trials for eluxadoline

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 2
AllerganPhase 2
AllerganPhase 4

See all eluxadoline clinical trials

Recent Litigation for eluxadoline

Identify potential future generic entrants

District Court Litigation
Case NameDate
Pfizer Inc. v. Lee2015-01-14
Novartis AG v. Lee2013-01-14
Allergan USA, Inc. v. Aurobindo Pharma Ltd.

See all eluxadoline litigation

Pharmacology for eluxadoline
Synonyms for eluxadoline
45TPJ4MBQ1
5-(((S)-2-AMINO-3-(4-CARBAMOYL-2,6-DIMETHYLPHENYL)-N-((S)-1-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL)PROPANAMIDO)METHYL)-2-METHOXYBENZOIC ACID
5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid
5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(4-phenyl-3H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
864821-90-9
AC-30329
AKOS030632800
AS-35135
Benzoic acid, 5-((((2S)-2-amino-3-(4-(aminocarbonyl)-2,6-dimethylphenyl)-1-oxopropyl)((1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)amino)methyl)-2-methoxy-
CHEBI:85980
CHEMBL2159122
CS-3855
D10403
DB09272
DEA No. 9725
DTXSID70235589
Eluxadoline (USAN)
Eluxadoline [USAN:INN]
EX-A1169
FT-0701295
GTPL7691
HY-12247
J3.535.064K
JNJ 27018966
JNJ-27018966
JNJ27018966
NCGC00485958-01
SB17335
SCHEMBL12971682
SCHEMBL17950908
truberzi
UNII-45TPJ4MBQ1
Viberzi
Viberzi (TN)
ZINC14210876
Paragraph IV (Patent) Challenges for ELUXADOLINE
Tradename Dosage Ingredient NDA Submissiondate
VIBERZI TABLET;ORAL eluxadoline 206940 2019-05-28

US Patents and Regulatory Information for eluxadoline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for eluxadoline

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1725537 PA2017005,C1725537 Lithuania   Start Trial PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537 LUC00007 Luxembourg   Start Trial PRODUCT NAME: ELUXADOLINE OU UN ENANTIOMERE, UN DIASTEREOMERE, UNRACEMATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/16/1126 20160921
1725537 PA2017005 Lithuania   Start Trial PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Merck
AstraZeneca
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.